Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. Measured by net revenue, Quintiles is the biopharma outsourcing services industry's largest company, with 2009 net revenue of almost US$3 billion. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics.
Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant, which we describe as the New Health. The industry's challenges include declining R&D productivity; increasing development costs; diminishing returns on marketing and sales; lower earnings; and an approaching "patent cliff" - an estimated $128 billion of branded revenues losing patent protection between 2009 and 2014. To succeed in the New Health, biopharma companies must increase their speed to market, maximise productivity, overcome complexity and, most importantly, deliver enhanced value for patients. Quintiles provides services and solutions to help companies achieve this transformation.
As biopharmaceutical companies increase their focus on Asia, Quintiles' combination of global experience and regional expertise has never been more important. Quintiles opened its first office in Asia-Pacific in 1993, and since that time, Quintiles has grown to more than 20 offices in 14 countries throughout the region. During that same timeframe, Quintiles has conducted 1,300 studies involving greater than 9,000 sites and more than 185,000 patients in the region. Through these efforts and experience, Quintiles is able to provide its customers with unmatched expertise and experience across a wide range of therapeutic areas, including cardiovascular disease, oncology, neurology, infectious disease and others. For more information, please visit www.quintiles.com.